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Aggrecan is a large proteoglycan bearing numerous chondroitin sulfate and keratan sulfate chains that endow articular
cartilage with its ability to withstand compressive loads. It is present in the extracellular matrix in the form of proteoglycan
aggregates, in which many aggrecan molecules interact with hyaluronan and a link protein stabilizes each interaction.
Aggrecan structure is not constant throughout life, but changes due to both synthetic and degradative events.
Changes due to synthesis alter the structure of the chondroitin sulfate and keratan sulfate chains, whereas those
due to degradation cause cleavage of all components of the aggregate. These latter changes can be viewed as
being detrimental to cartilage function and are enhanced in osteoarthritic cartilage, resulting in aggrecan depletion
and predisposing to cartilage erosion. Matrix metalloproteinases and aggrecanases play a major role in aggrecan
degradation and their production is upregulated by mediators associated with joint inflammation and overloading.
The presence of increased levels of aggrecan fragments in synovial fluid has been used as a marker of ongoing cartilage
destruction in osteoarthritis. During the early stages of osteoarthritis it may be possible to retard the destructive process
by enhancing the production of aggrecan and inhibiting its degradation. Aggrecan production also plays a central role
in cartilage repair techniques involving stem cell or chondrocyte implantation into lesions. Thus aggrecan participates
in both the demise and survival of articular cartilage.
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This review describes the role of aggrecan in the function of
articular cartilage and how this role is perturbed in the osteo-
arthritic (OA) joint. It explains the structure/function
relationship between the various regions of the aggrecan
molecules and how these are altered by synthetic and cata-
bolic events that occur throughout life and in the diseased
joint. It is clear that a view of cartilage function based on the
contribution of one molecule will be somewhat biased, but it
is also arguable that no molecule plays a more important role
than aggrecan. Without it the tissue could not withstand the
rigours of joint loading and its decreased abundance marks
the onset of the tissue decline associated with the OA joint.
Review
Articular cartilage, aggrecan and OA
Articular cartilage is the white, smooth, lustrous connect-
ive tissue that covers the surfaces of bones where they* Correspondence: proughley@shriners.mcgill.ca
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reproduction in any medium, provided the origmeet in diarthrodial joints. It serves two major functions;
to provide almost frictionless motion and to counteract
the impact of the compressive forces experienced across
the joint during use. The first of these functions is not
usually associated with aggrecan, but relates to the unique
collagen fiber organization at the articular surface and the
presence of lubricin and hyaluronan (HA)/phospholipid
complexes that aid in joint lubrication (Gleghorn et al.
2009; Wang et al. 2013a). However, aggrecan does play a
role in fluid pressurization of the cartilage which supports
the articular surface and so may facilitate its function
(Dabiri and Li, 2013; Moore and Burris, 2014). The ability
to resist compression is intimately associated with the
high abundance of aggrecan throughout the extracellular
matrix of articular cartilage beneath its superficial zone.
Aggrecan is a proteoglycan, and in common with all
proteoglycans it possesses a core protein with covalently
attached sulfated glycosaminoglycan (GAG) chains. Aggre-
can does not exist in isolation within the extracellular
matrix, but occurs in the form of proteoglycan aggregatesThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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composed of a central filament of HA with multiple
aggrecan molecules attached to it non-covalently via
one terminus of their core proteins (Figure 1). The
interaction between the aggrecan core protein and HA
is stabilized by the presence of a link protein that inter-
acts with both the aggrecan and HA. The GAG chains
provide aggrecan with its high anionic charge whereas
aggregation endows it with a large size. Both the charge
and size properties are essential for normal aggrecan
function and hence articular cartilage function.
The OA joint is characterized by catabolic processes
that degrade both the HA backbone of the aggregate and
the core protein of the aggrecan molecules, so impairing
aggrecan function and predisposing the articular cartilage
to erosion. Such degradation is associated with protein-
ases, hyaluronidases and free radicals.
Structure of aggrecan
The core protein of aggrecan consists of three disulfide-





Figure 1 Structure of proteoglycan aggregates. The proteoglycan aggr
and link proteins (LP) attached to it. The domains of the aggrecan core pro
domain; KS, keratan sulfate-rich domain; CS1 and CS2, chondroitin sulfate-rintervening extended regions (Sandy et al. 1990) (Figure 2).
The G1 region resides at the amino terminus of the core
protein and is responsible for the interaction with HA. It
is formed from three disulfide-bonded domains termed A,
B and B′, with the B domains being responsible for the
interaction with HA and the A domain being responsible
for the interaction with link protein (Matsumoto et al.
2003; Watanabe et al. 1997). The G2 region is composed
of two B-like domains, but does not have the ability to
interact with HA and its functional role is at present
unclear (Fosang and Hardingham, 1989). It is separated
from the G1 region by the interglobular domain (IGD).
The IGD is a prominent site for proteolysis, with many
proteinases being able to cleave between the G1 and
G2 regions (Fosang et al. 1992). The G1 and G2 regions
and the IGD may be substituted with several N-linked
and O-linked oligosaccharides or keratan sulfate (KS)
(Barry et al. 1995).
The G2 and G3 regions are separated by a long GAG-
attachment region that is subdivided into three domains





egate is depicted as a central hyaluronan (HA) filament with aggrecan
tein are indicated. G1, G2 and G3, globular regions; IGD, interglobular
ich domains.
Figure 2 Core protein domains of aggrecan. Upper panel: The domains of the aggrecan core protein are depicted. G1, G2 and G3, globular
regions; IGD, interglobular domain; KS, keratan sulfate-rich domain; CS1 and CS2, chondroitin sulfate-rich domains. The globular regions are divided into
their disulfide-bonded domains. A, link protein-binding domain; B and B′, hyaluronan-binding domains for G1 and homology domains for G2;
E, epidermal growth factor-like domains; L, lectin-like domain; C, complement regulatory protein-like domain. Lower panel: The coding exon
arrangement of the human aggrecan gene is depicted and the regions of the core protein encoded by each exon is indicated.
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acids, with each repeat possessing a proline-serine se-
quence. Each serine residue can potentially act as the
attachment site for O-linked oligosaccharides that form
the linkage region for KS. The KS-rich domain is followed
by the chondroitin sulfate (CS)-rich domain, which is
divided into two subdomains (CS1 and CS2) that differ
in amino acid sequence. The CS1 domain is composed
of repeats of nineteen amino acids, with each repeat
possessing two serine-glycine sequences. Each serine
residue in the repeats can potentially act as an attachment
site for CS. The CS2 domain also possesses serine-glycine
sequences that can act as the attachment site for CS.
Because of their differing amino acid sequences, the
CS1 and CS2 domains have differing susceptibilities to
proteolysis. A typical aggrecan molecule may contain
up to 100 CS chains and a lower number of KS chains.
The sulfated nature of the CS and KS provide the
aggrecan with its high anionic charge.
The CS2 domain is followed by the G3 region, which
resides at the carboxy terminus of the core protein. The
G3 region is composed of two epidermal growth factor
(EGF)-like domains, one C-type lectin-like domain, and
one complement regulatory protein (CRP)-like domain.
The G3 region appears to be essential for normal traf-
ficking of the aggrecan within the chondrocyte and for
its secretion into the extracellular matrix (ECM) (Zheng
et al. 1998). It is unclear whether each domain of the G3
region possesses a unique function within the ECM. The
lectin-like domain does have the ability to interact with
a variety of ECM proteins, such as tenascins and fibulins
(Aspberg, 2012), and could potentially play a role in
anchoring the aggrecan within the tissue. However,
the G3 region is absent from many mature aggrecan
molecules in the ECM due to its proteolytic cleavage
(Dudhia et al. 1996a).
The domain structure of the aggrecan core protein is
reflected in the exon organization of its gene (Valhmu
et al. 1995) (Figure 2). The human aggrecan gene consists
of 19 exons. The G1 region is encoded by exons 3–6, withexon 3 encoding the A domain, exons 4 and 5 encoding
the B domain and exon 6 encoding the B′ domain. The
IGD is encoded by exon 7. The G2 region is encoded by
exons 8–10, with exons 8 and 9 encoding the B domain
and exon 10 encoding the B′ domain. The GAG attach-
ment region is encoded by exons 11 and 12, with exon 11
encoding the first part of the KS-rich domain, and the
large exon 12 encoding the remainder of the KS-rich
domain plus the CS1 and CS2 domains. The hexapeptide
repeats of the KS-rich region are encoded by exon 12. The
G3 region is encoded by exons 13–19, with exons 13
and 14 each encoding an EGF-like domain, exons 15–17
encoding the lectin-like domain, and exon 18 encoding
the CRP-like domain.
While the domain organization of aggrecan is conserved
amongst different species, there are species variations in
its core protein structure (Doege et al. 1987; Hering et al.
1997; Li et al. 1993; Walcz et al. 1994). Foremost amongst
these are the variations in the number of repeats in both
the KS-rich and CS domains. The number of KS-rich
repeats varies from 4 in the rat to 23 in the bovine, with
the human possessing 13 (Barry et al. 1994). In the CS1
domain there are 17 repeats in the rat, 23 in the mouse
and 27 in the bovine. The human is unique in possessing
length polymorphism in its CS1 domain, with the number
of repeats varying from 13 to 33, though the majority
of individuals have 26–28 repeats (Doege et al. 1997).
In the human it has been shown that the KS-rich domain
is devoid of CS and the CS1 domain is devoid of KS
(Rodriguez et al. 2006). The human CS2 domain contains
at least one KS chain adjacent to the G3 region. In the
bovine this site is occupied by CS. The human also
appears to be unique in possessing two exons encoding
for EGF-like domains. In other species studied, gen-
omic sequence variations prevent expression of the
EGF1 domain and only the EGF2 domain is present
(Fülöp et al. 1996). In the human, the G3 region has a
variable structure due to alternative splicing of both
EGF-like domains and the CRP-like domain (Grover
and Roughley, 1993).
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The HA that forms the core of the proteoglycan aggre-
gate is not unique to cartilage, but is ubiquitous in its
presence (Fraser et al. 1997). It is formed at the plasma
membrane of most cells by a hyaluronan synthase (Has)
(Weigel and DeAngelis, 2007). Mammals possess 3 Has
(Has1, Has2 and Has3) (Itano et al. 1999), with Has2
being the predominant form in cartilage (Recklies et al.
2001). The HA is synthesized in the cytosol and the
growing chain is extruded directly into the extracellular
environment (Hubbard et al. 2012), where it forms a
coat around the chondrocytes (Knudson et al. 1999). It
is not clear how HA is released from the cell surface or
where interaction with aggrecan takes place. A typical HA
chain may possess 10,000 disaccharide units, with each
G1 domain interacting with a decasaccharide region
(Hascall and Heinegård, 1974). Individual aggrecan
molecules may be spaced about 50 disaccharides apart
due to the size exclusion properties of their GAGs.
The link protein (LP) that stabilizes the proteoglycan
aggregate has a domain structure analogous to that of
the G1 region of aggrecan (Neame and Barry, 1993)
(Figure 3). The A domain interacts with the A domain
of the aggrecan G1 region and the B domains interact
with HA. In the ECM, the link protein exists in three
forms (LP1, LP2 and LP3) (Mort et al. 1985). LP1 has two
N-linked oligosaccharides on residues 6 and 41, whereas
LP2 has one N-linked oligosaccharide on residue 41. LP3
is formed by proteolytic cleavage between the two sites
for N-linked oligosaccharide substitution. There is no
evidence for any functional difference between the three
LP forms. In addition to stabilizing the proteoglycan
aggregates, the link protein also serves two additional
functions. First, it forms a coat along the HA that helps
protect the HA from degradation by hyaluronidases or
free radicals (Rodriguez and Roughley, 2006). Second, it
participates in the process of delayed aggregation (Oegema
1980). The G1 region of newly secreted aggrecan doesFigure 3 Structure of link protein. Link protein is depicted with
three disulfide-bonded domains (A, B and B′) and two N-linked
oligosaccharides (Y) in its amino terminal region. The amino terminus
(N) and carboxy terminus (C) of the protein are indicated.not interact with HA, but acquires this ability following
interaction with link protein in a process that appears to
involve disulfide exchange within the G1 region (Melching
and Roughley, 1990). Delayed aggregation may allow
the aggrecan to escape retention by the HA coat at the
cell surface of the chondrocyte and diffuse into the
more remote ECM before aggregation occurs.
Structure/function relationships of aggrecan
When aggrecan finds itself in an aqueous environment
its swells as the sulfated GAG chains become hydrated
in an attempt to expand their molecular domain and
increase their separation from one another. Within the
ECM, such swelling is resisted by the collagen fibrils that
form the framework of the cartilage. If sufficient aggrecan
is present, an equilibrium will be attained with the
swelling of the aggrecan being balanced by the tensile
forces that it induces upon stretching of the collagen
fibrils (Figure 4). For optimal cartilage function it is
essential that aggrecan concentration be high enough
so that such an equilibrium be attained. Upon compressing
articular cartilage, the equilibrium is perturbed. Compres-
sion displaces water and as the size of the proteoglycan
aggregates limits their free diffusion within the tissue,
the aggrecan at the site of compression is bought into
closer proximity. This increases the swelling potential of
the aggrecan, and upon removal of the compression the
aggrecan will re-swell and restore the original equilibrium.
Thus normal articular cartilage function requires a high
concentration of aggrecan, a high degree of aggrecan
sulfation, and the ability to form large aggregates. Each
of these properties is impaired in the OA joint.
The movement of water within the cartilage during
cyclical compressive loading is thought to aid in the
nutrition of the chondrocytes. As the cartilage is an
avascular tissue, its nutrients must arise from the bathing
synovial fluid by diffusion and its waste products must be
expelled in a similar manner. The displacement of water
upon compression aids in waste removal, and the return
of water following removal of compression aids in nutrient
supply. Obviously static loading cannot participate in
such a mechanism. However, while dynamic loading
may be beneficial to cartilage, its value will depend on
its magnitude, frequency and duration. Loading at too
high a magnitude may adversely influence the cells,
resulting in cell death and ECM destruction. Cartilage
overloading has long been thought to be linked to the
onset of OA (Mitchell and Cruess, 1977).
Variations in aggrecan structure due to synthesis
The structure of aggrecan does not remain constant
throughout life, but undergoes extensive changes due
to variations in synthesis both within the chondrocytes
and the ECM (Figure 5). The cellular changes due to
Figure 4 The function of aggrecan in articular cartilage. Proteoglycan aggregates are depicted as being entrapped by collagen fibrils. In the
relaxed state the aggregates swell as the anionic chondroitin sulfate and keratan sulfate chains draw water into the tissue until an equilibrium is
attained in which swelling is balance by tensile forces in the collagen fibrils. Under compression, water is displaced and the chondroitin sulfate
and keratan sulfate chains are brought into closer proximity, so increasing their swelling potential and balancing the applied load. The increased
swelling potential is dissipated upon removal of the load as the original equilibrium is restored.
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and are essentially complete by 20 years of age. They affect
mainly the length and sulfation pattern of the CS and KS
chains on the aggrecan core protein (Brown et al. 1998;
Plaas et al. 1997; Roughley et al. 1987; Roughley and
White, 1980). With increasing age, the CS chains become
shorter in length whilst the KS chains become longer. In
the case of the KS chains it appears that sites occupied by
O-linked oligosaccharides become occupied by KS, so
increasing KS chain substitution (Santer et al. 1982). It is
not clear if the pattern of CS chain substitution changes
with age, or whether all potential CS attachment sites are
always occupied. The divergent changes in CS and KS
chain length may serve to maintain the charge of the







Figure 5 Age-related changes in aggrecan structure. Changes in aggre
due to synthesis result in an increase in chondroitin sulfate length and a d
truncation of the aggrecan core protein by removal of the G3 region, cleav
and G2 regions.in KS reflects the avascular nature of mature articular
cartilage, as KS does not require an oxidation step to
generate a uronic acid for its constituent disaccharides
(Balduini et al. 1992). The major change in sulfation
pattern affects CS. In the human, the degree of sulfation
increases throughout fetal life, and by birth 4 and 6-
sulfation of the N-acetyl galactosamine residues occurs in
equal abundance. Following birth, the sulfation pattern
slowly changes to predominantly 6-sulfation. There is also
a change in the sulfation pattern of KS, with increased
sulfation of it galactose residues. It is not clear whether
these changes in sulfation are of any significance in
cartilage function.
There is also one synthetic change in aggrecan structure
that takes place in the ECM, involving non-enzymiccan structure due to synthesis and degradation are depicted. Changes
ecrease in keratan sulfate length. Changes due to degradation result in
age within the GAG-attachment region, and cleavage between the G1
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interaction of a reducing sugar, such as glucose or ribose,
with lysine residues in the core protein, and the ultimate
formation of advanced glycation end-products (Cloos and
Christgau, 2002), such as pentosidine, which accumulate
with age (Verzijl et al. 2001). Such glycation can modify
the lysine residues within the G1 region that facilitate the
interaction with HA, and so prevent aggregation. More
importantly, it can result in dissociation of the aggregates
that are already formed (Figure 6). Thus glycation could
adversely influence cartilage function.
Variations in aggregate structure due degradation
The major changes in aggregate structure taking place
in the ECM are due to degradation, and may affect all
components of the aggregate (Figure 6). The protein/
carbohydrate makeup of the proteoglycan aggregate
renders it susceptible to multiple degradative mechanisms.
Most importantly the protein component can be cleaved by
a diverse series of proteolytic enzymes and the glycosami-Proteolysis
Non-enz
glycati
Figure 6 Mechanisms of proteoglycan aggregate degradation. A prote
Degradation is represented following proteolysis of the aggrecan core prot
protein, and hyaluronidase or free radical cleavage of hyaluronan.noglycan component, in particular the HA, is suscep-
tible to the action of glycosyl hydrolases. In addition,
both the protein and polysaccharide constituents undergo
modification by reactive oxygen species (ROS) which can
lead to chain fragmentation.
The extended nature of the aggrecan core protein makes
it a general target for degradation by proteolytic enzymes.
The huge repertoire of proteases present in the body can
be organized into six classes based on catalytic mechanism
(Rawlings et al. 2012). In vitro, aggrecan is susceptible to
cleavage by almost all known proteases and cleavage
sites have been reported for members of four of these
classes, serine, cysteine, aspartic and metalloproteases. In
most cases the known selectivities of specific proteases
are reflected in the novel N- and C-terminal sequences
generated by their action. In the case of proteases known
to be active in cartilage, correlation of such cleavage
sites with the sequence termini determined in aggrecan
fragments isolated from human articular cartilage and




oglycan aggregate bearing five aggrecan molecules is depicted.
ein, non-enzymic glycation of the aggrecan core protein and link
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in cartilage degradation in vivo (Table 1). Such evidence
points to a role for particular metallo-, cysteine and serine
proteases in the degradation associated with aggrecan
turnover in normal physiology and OA. Additional pro-
teolytic cleavage sites have been identified by digestion of
aggrecan in vitro, and the presence of the correspond-
ing products in vivo has been inferred based on the
molecular sizes of aggrecan fragments extracted from
cartilage or isolated from synovial fluid (Struglics and
Hansson, 2012).
Current evidence points to members of two families of
metalloproteases, the MMP (matrix metalloproteinase) and
ADAMTS (a disintegrin and metalloproteinase with throm-
bospondin motifs) families, as being the most important
mediators of aggrecan degradation (Sztrolovics et al. 1997).
These are zinc ion dependent enzymes that are multido-
main proteins where additional non-catalytic components
serve to help select and anchor the substrate protein to
the catalytic unit to facilitate proteolysis (Figure 7). MMPs
1, 8, and 13 are true collagenases, where their ancillary
hemopexin domains are essential for the ability of these
enzymes to degrade triple helical collagen. Other MMPs
such as MMP3 (stromelysin) are effective general prote-
ases and cleave at various sites along the aggrecan core
protein, including the IGD (Figure 8) (Troeberg and
Nagase, 2012). It has been proposed that MMPs are
mainly involved in normal aggrecan turnover (Struglics
and Hansson, 2012). Members of the ADAMTS family
of metalloproteases (ADAMTS4 and 5) that were
originally termed “aggrecanases” degrade aggrecan at a
series of specific locations in the IGD and the CS2Table 1 Sequence termini on cleavage fragments of
human aggrecan for which anti-neoepitope antibody
reactivity, or direct sequencing, have demonstrated the
presence of specific products in vivo
Region Sequence1 Proteinase Reference
IGD DIPEN360 MMP (Flannery et al. 1992)
361FFGVG MMP (Fosang et al. 1995)
ITVQTV375 HtrA1 (Chamberland et al. 2009)
ITEGE392 ADAMTS4/5 (Lark et al. 1997)
393ARGSV ADAMTS4/5 (Sandy et al. 1992)
KS-rich VPGVA709 Calpain (Maehara et al. 2007)
CS1 VGDLS954 Calpain (Struglics et al. 2006)
CS2 ASELE1564 ADAMTS4/5 (Sandy and Verscharen, 2001)
FKEEE1733 ADAMTS4/5 (Sandy and Verscharen, 2001)
1838AGEGP ADAMTS4/5 (Dufield et al. 2010)
1939LGQRP ADAMTS4/5 (Sandy and Verscharen, 2001)
1Aggrecan residue numbering is based on the human aggrecan sequence
(Uniprot P16112, derived from the cDNA) which includes the signal peptide.domain. These cleavages have been shown to be particu-
larly prevalent in the course of cartilage destruction in
arthritis.
In addition to the metalloproteases, there is direct
evidence for the involvement of specific cysteine and
serine proteases in cartilage turnover. The presence of
m-calpain in human cartilage has been reported for some
time and it is clear that much of the fragmented aggrecan
present in adult human cartilage, which consists of the
G1-IGD-G2 regions, is the product of calpain action
(Maehara et al. 2007). Calpain is a multidomain calcium
dependent protease and would be active in the cartilage
extracellular matrix. There is accumulating evidence
that in addition to the action of MMP collagenases, the
cysteine protease cathepsin K also plays a role in colla-
gen breakdown in human cartilage. In contrast to the
other proteases considered so far, cathepsin K consists
of a single catalytic unit but forms a defined complex with
chondroitin 4-sulfate which increases its stability and is
essential for its ability to degrade triple helical collagen.
Since cathepsin K is known to cleave aggrecan in vitro
(Hou et al. 2003), it is likely to contribute to this process
in vivo.
Recently direct analysis of human osteoarthritic cartilage
extracts identified the interesting serine protease HtrA1
and aggrecan degradation products characteristic of its
action in the IGD (Chamberland et al. 2009). Since ele-
vated levels of this protease are seen in osteoarthritis
(Grau et al. 2006) and given its ability to cleave many
other extracellular matrix components (Eigenbrot et al.
2012), it may complement the well accepted role of the
metalloproteases in disease progression.
While there is little evidence for degradation of CS and
KS within the ECM, the size of the HA decreases with age
(Holmes et al. 1988), presumably due to depolymerization
by hyaluronidases or free radicals (Stern et al. 2007). A
series of genes have been identified coding for glycosyl
hydrolase-like proteins termed hyaluronidases (Csoka
et al. 2001; Stern et al. 2007). However only two of these
appear to be true hyaluronidases relevant to extracellu-
lar matrix degradation. While hyaluronidase-1 cleaves
hyaluronan and chondroitin sulfate very effectively, it
has a very low pH optimum as befits its normal lyso-
somal location. In contrast hyaluronidase-2 is active at
neutral pH and at least a portion of it is located at the
cell surface (Miller et al. 2006). Hyaluronidase-2 has
been shown to cleave hyaluronan into relatively large
fragments which are then taken up by the cell and
degraded by hyaluronidase-1 and β-hexosaminidase
(Gushulak et al. 2012).
Proteolysis causes extensive modification of the aggre-
can core protein. This involves removal of the G3 region
(Dudhia et al. 1996b), truncation within the GAG-
attachment region and ultimately accumulation of G1
Figure 7 Domain structure of proteases that participate in aggrecan core protein degradation. The mature (active) forms of the enzymes
are illustrated. The catalytic units are shown in magenta, with the catalytic amino acid residues (C, H, N, D,S) or co-factor (Zn2+) indicated. Ancillary
domains, some of which are involved in substrate recognition, are also depicted. TS, thrombospondin-like; PEF, penta EF-hand (calcium binding domain);
IGFBP, insulin-like growth factor binding protein-like; PDZ, protein/protein interaction domain. The functional form of calpain is a heterodimer of the large
and small subunit shown, and that of HtrA1 is a homotrimer.
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1985) (Figure 5). In the case of link protein, proteolysis
results in the accumulation of LP3 and a concomitant
decrease in LP1 and LP2. In vitro, many proteinases are
capable of forming LP3, but in vivo MMPs play a major
role (Nguyen et al. 1991). Aggrecanases are not able to
cleave link protein (Roughley et al. 2003). While cleavage of
link protein may be of no functional consequence, cleavage
of aggrecan and HA are detrimental to cartilage function as
they reduce both the size and charge of the aggregates.
Variations in aggrecan structure in OA
Articular cartilage in the OA joint is subjected to increased
catabolism due to the presence of various cytokines that
may arise from the chondrocytes themselves or by infiltra-
tion from the inflamed synovium (Goldring and Goldring,
2004). Foremost amongst these cytokines are interleukin 1
(IL1) and tumor necrosis factor α (TNFα), which not
only stimulate the production of proteinases but also
down-regulate aggrecan production. These inflammatory
cytokines are associated with the production of aggreca-
nases and MMPs, which degrade the aggrecan core protein
(Troeberg and Nagase, 2012). The combined effect of





Figure 8 Proteolytic cleavage sites within the aggrecan core protein.
determined in vitro by the action of proteases known to be active in cartilaresults in aggrecan loss from the ECM and impairment
of articular cartilage function. Subsequently, collagenases
(MMP1 and MMP13) degrade the collagen fibrils of the
tissue, initiating tissue fibrillation and eventual erosion.
Even if joint inflammation is resolved, it is likely that the
depletion in aggrecan results in adverse consequences
to loading, with the production of proteinases by the
chondrocytes. The initiating event that causes aggrecan
depletion may be either joint inflammation or joint over-
loading. Once damage is initiated, articular cartilage has
little ability for endogenous repair and further damage
appears to be an inevitable consequence.
While ineffective, articular cartilage does mount a limited
repair response characterized by some cell proliferation and
some new proteoglycan synthesis around the resulting cell
clusters. Analysis of the aggrecan from OA cartilage shows
a CS sulfation pattern more typical of juvenile cartilage
than the mature adult (Caterson et al. 1990), suggesting
that OA alters the phenotype of the resident mature
chondrocytes or that it induces the formation of new
immature chondrocytes. As articular cartilage is known
to possess progenitor cells (Williams et al. 2010), these
could be the source for cell proliferation and differentiation
into immature chondrocytes.A A A M
The location of cleavage sites on the human aggrecan core protein
ge in vivo are shown. A, ADAMTS4/5; C, calpain; H, HtrA1; M, MMPs.
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Following proteolytic cleavage of the aggrecan core protein
at any site, two fragments are generated. One fragment will
possess a G1 region and remain bound to HA, whereas the
other is no longer able to interact with HA. This latter
non-aggregating fragment is free to diffuse within the
ECM and is rapidly lost into the synovial fluid. In contrast,
fragments that remain bound to HA can reside in the
tissue for many years (Maroudas et al. 1998). It has been
estimated that the G1 regions that form the end product
of proteolytic truncation of the aggrecan core protein have
a half-life of about 20 years. This can be viewed as an
impediment to repair, as the G1 regions cannot participate
in the load bearing function of the cartilage, yet they
occupy space on the HA that could be used for binding
newly synthesized aggrecan.
The aggrecan fragments that diffuse into the synovial
fluid have been used as biomarkers in OA patients, with
the premise that a higher concentration of fragments in
the synovial fluid reflects enhanced degradation within
the cartilage. This does assume that other factors, such
as the rate of clearance from the synovial fluid or the
secretion of newly synthesized aggrecan from the cartilage,
are of lesser importance. In principle, the efficacy of drug
therapy can be followed by monitoring the decline in frag-
ment abundance. Fragment abundance can be monitored
by a variety of techniques. The simplest techniques involve
the quantification of sulfated GAG content by the dimethyl
methylene blue (DMMB) assay (Farndale et al. 1986)
and analysis of KS by immunoassay (Campion et al.
1991). An immune assay has also been described for a
CS sulfation variant (846 epitope) that is characteristic
of juvenile and OA cartilage (Poole et al. 1994). Finally,
neoepitope immunoassays have been developed to
specifically analyse for aggrecan degradation products
resulting from either MMP or aggrecanase cleavage
(Fosang et al. 2003; Germaschewski et al. 2014; Hughes
et al. 1995).
Repair of articular cartilage
While joint replacement with a prosthesis may be the
preferred treatment for late stage OA where most of the
articular cartilage has been eroded, biological repair is
an attractive alternative for more focal early lesions.
Current techniques tend to fall into two categories: those
that are cartilage-based and those that are cell-based
(Camp et al. 2014). The cartilage-based procedures
include mosaicplasty, single osteochondral autografts and
osteochondral allografts, where a mature articular cartilage
is implanted into the lesion so that the composition of
the repair tissue is equivalent to that which was eroded.
The cell-based techniques include microfracture and
autologous chondrocyte implantation (ACI), where the
cells that will generate the repair cartilage are eitherbone marrow-derived mesenchymal stem cells or mature
articular chondrocytes, respectively. When using stem
cells, the structure and abundance of aggrecan and the
composition of the cartilage ECM that is formed is
immature and may not be ideal for withstanding the
rigours of adult life. The use of mature chondrocytes may
help resolve some of these problems, but the cartilage
structure is still somewhat immature as age-dependent
events, such as collagen cross-linking, that help reinforce
the tissue are not fully established. A means of maturing
the cell-derived cartilage would enhance its repair value.
However, whichever technique is used, it is essential that
the factor causing the degeneration be treated or elimi-
nated if future degeneration of the repair tissue is to be
avoided (Moran et al. 2014).
In the early stages of OA, prior to extensive collagen
damage, it may be possible to retard or even reverse the
degenerative process by the administration of agents that
promote aggrecan synthesis and prevent its degradation.
Development of specific small molecule inhibitors for
MMP and ADAMTS family members has been an
extremely active area for several decades. Although there
have been setbacks (Clark and Parker, 2003), new highly
specific compounds for the inhibition of ADAMTS5 are
being produced (Deng et al. 2012) so there is still hope
that products of this approach may reach the clinic.
Nutriceuticals, such as glucosamine, have been touted as
therapeutic agents, though their clinical efficacy remains
to be proven (Salazar et al. 2014). Some growth factors,
such as transforming growth factor β (TGFβ) and bone
morphogenetic protein 7 (BMP7) have the desired prop-
erties, but they are expensive to use and could have
unwanted side effects. However, local delivery of single
or a combination of growth factors, including insulin-like
growth factor I (IGFI), fibroblast growth factor-2 (FGF2),
TGFβ and BMPs, by way of gene therapy may overcome
these deficits (Shi et al. 2012; Trippel et al. 2007). An eco-
nomically attractive alternative to growth factors may be
LinkN (McKenna et al. 1998), which represents the amino
terminal 16 amino acids of link protein. It occurs naturally
from the formation of LP3, but can be produced cheaply
using a peptide synthesizer. It appears to function through
the BMP receptor system (Wang et al. 2013b), but unlike
BMPs does not stimulate osteogenesis (Antoniou et al.
2012). Only in the future will we know whether such
agents live up to their current promise.Conclusions
Aggrecan plays an essential role in the function of articu-
lar cartilage and is a central participant in its destruction
in the OA joint. Agents that prevent aggrecan degradation
and restore its production may play a future role in the
treatment of early stage OA.
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